Royalty Pharma (NASDAQ:RPRX) EVP George Lloyd Sells 30,654 Shares

Royalty Pharma PLC (NASDAQ:RPRX) EVP George Lloyd sold 30,654 shares of Royalty Pharma stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $38.50, for a total value of $1,180,179.00. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Royalty Pharma Trading Up 0.4%

NASDAQ:RPRX opened at $38.60 on Friday. The company has a quick ratio of 3.48, a current ratio of 3.48 and a debt-to-equity ratio of 0.89. Royalty Pharma PLC has a 52-week low of $24.32 and a 52-week high of $41.24. The stock’s 50 day moving average price is $38.36 and its 200 day moving average price is $36.74. The company has a market capitalization of $22.28 billion, a PE ratio of 29.24, a P/E/G ratio of 2.02 and a beta of 0.47.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share for the quarter, beating the consensus estimate of $1.11 by $0.06. The business had revenue of $609.29 million during the quarter, compared to the consensus estimate of $765.01 million. Royalty Pharma had a return on equity of 26.36% and a net margin of 32.51%. On average, research analysts anticipate that Royalty Pharma PLC will post 4.49 EPS for the current year.

Royalty Pharma Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th were given a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend was Friday, November 14th. Royalty Pharma’s dividend payout ratio (DPR) is presently 66.67%.

Hedge Funds Weigh In On Royalty Pharma

Large investors have recently modified their holdings of the business. Hudson Bay Capital Management LP boosted its stake in shares of Royalty Pharma by 1.0% in the third quarter. Hudson Bay Capital Management LP now owns 29,384 shares of the biopharmaceutical company’s stock valued at $1,037,000 after buying an additional 289 shares in the last quarter. Tudor Investment Corp ET AL raised its position in Royalty Pharma by 34.4% in the third quarter. Tudor Investment Corp ET AL now owns 863,835 shares of the biopharmaceutical company’s stock worth $30,476,000 after acquiring an additional 221,099 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Royalty Pharma by 28.1% in the third quarter. JPMorgan Chase & Co. now owns 1,759,620 shares of the biopharmaceutical company’s stock valued at $62,079,000 after acquiring an additional 386,108 shares during the period. CIBC Bancorp USA Inc. acquired a new stake in Royalty Pharma in the third quarter valued at $480,000. Finally, Alpine Global Management LLC purchased a new stake in shares of Royalty Pharma during the 3rd quarter worth $513,000. 54.35% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

RPRX has been the subject of several recent research reports. TD Cowen increased their target price on shares of Royalty Pharma from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Cowen reaffirmed a “buy” rating on shares of Royalty Pharma in a research report on Thursday, December 11th. Wall Street Zen lowered Royalty Pharma from a “strong-buy” rating to a “buy” rating in a report on Friday, November 28th. The Goldman Sachs Group began coverage on Royalty Pharma in a report on Tuesday, September 30th. They set a “buy” rating and a $42.00 price target for the company. Finally, Weiss Ratings lowered shares of Royalty Pharma from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Saturday, October 25th. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, Royalty Pharma currently has an average rating of “Moderate Buy” and a consensus target price of $45.60.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.